Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Cancer. 2011 Aug;47(12):1846-51. doi: 10.1016/j.ejca.2011.04.020. Epub 2011 May 18.

Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.

Author information

1
Medical Oncology Department, University Hospital La Paz, Madrid, Spain. mariamesal@gmail.com

Abstract

Despite multiple advances in prostate cancer therapy, treatment options for castration resistant disease are very limited. While data from recent studies are encouraging, there is no drug that has significantly improved results of standard chemotherapy. Some of the most consistent results are provided by antiangiogenic agents, showing high response rates and manageable toxicity. We describe some of the main therapeutic angiogenesis inhibitors in metastatic castration resistant prostate cancer. These agents include vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, antiangiogenic and inmunomodulatory agents and endothelin receptor antagonists.

PMID:
21600762
DOI:
10.1016/j.ejca.2011.04.020
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center